Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cladribine-based Salvage Chemotherapy in Relapse/Refractory AML and High Risk MDS
NCT03150004Phase 2Terminated
- Sponsor
- Medical College of Wisconsin
- Start
- Jun 2017
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of cladribine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (2 arms), sponsored by Medical College of Wisconsin. Primary endpoints: Minimal Residual Disease Complete Remission at 35 days, Subjects Receiving a Second Cycle at 70 days and 2 more. Started Jun 2017; status: terminated.
02
Drugs
cladribine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT03150004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03150004.